| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
2 companies
Kevin Bitterman is Director at EDIT, with reported holdings spanning 2 companies. Kevin Bitterman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $8.3M at current prices.
Our model assigns Kevin Bitterman a middling insider score of 61/100, based on 25 past trades. Over a 12-month horizon, 55.6% of those trades were profitable, with an average 12-month return of -0.3%.
Kevin Bitterman's largest disclosed position is in EDIT as Director, worth about $7.3M. The EDIT filings lean toward selling, a net 1,859,029 shares.
Kevin Bitterman has 35 Form 4 filings on record from February 2016 to October 2026, across 2 companies: Director at Disc Medicine (IRON), 2022–2026; Director at Editas Medicine (EDIT), 2016–2017.
The 120 reported transactions were 106 open-market sales, 6 option or other derivative awards, 4 option exercises and 3 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $8.0M and 27 sales worth about $96.2M.
The only open-market purchase was 222,223 shares of IRON at an average $36.00 on June 17, 2024, about $8.0M. Twelve months later IRON was up 12%.
The largest open-market sale was 1,000,000 shares of EDIT at an average $17.00 on May 22, 2017, about $17.0M.
7 of the 19 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 12 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | IRON Disc Medicine, Inc. | Director | Sell10b5-1 | 41,825 | $80.13 | $3,351,273.95 | -76.3% | - | - | |
| Sep 11, 2026 | IRON Disc Medicine, Inc. | Director | Sale+OE | 27,136 | $70.11 | $1,902,504.96 | - | - | - | |
| Sep 4, 2026 | IRON Disc Medicine, Inc. | Director | Sell10b5-1 | 1,689 | $79.96 | $135,052.44 | -11.2% | - | - | |
| Sep 3, 2026 | IRON Disc Medicine, Inc. | Director | Sell10b5-1 | 54,496 | $80.15 | $4,367,944.38 | -80.2% | - | - | |
| Dec 17, 2025 | IRON Disc Medicine, Inc. | Director | Sell | 754 | $91.47 | $68,968.38 | -5.1% | -31.4% | - | |
| Dec 16, 2025 | IRON Disc Medicine, Inc. | Director | Sale+OE | 184,123 | $91.56 | $16,858,639.38 | -92.9% | -33.4% | - | |
| Oct 17, 2025 | IRON Disc Medicine, Inc. | Director | Sell | 105,033 | $86.83 | $9,120,424.81 | -21.4% | -21.0% | -36.8% | |
| Oct 8, 2025 | IRON Disc Medicine, Inc. | Director | Sell | 90,000 | $70.14 | $6,312,500.51 | -15.2% | +10.1% | -13.5% | |
| Aug 22, 2025 | IRON Disc Medicine, Inc. | Director | Sell10b5-1 | 2,287 | $61.03 | $139,575.61 | -0.4% | +49.7% | +32.2% | |
| Aug 14, 2025 | IRON Disc Medicine, Inc. | Director | Sell10b5-1 | 32,174 | $61.11 | $1,966,286.18 | -5.1% | +41.7% | +29.8% |